A supervised analysis of gene-expression profiles of purified clonal plasma cells from patients with systemic light-chain amyloidosis (AL) who have high or low levels of serum free lambda light chains

被引：0
|
作者：
Comenzo, R. L. [1 ]
Zhou, P. [1 ]
Fleisher, M. [1 ]
Olshen, A. B. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2006年 / 13卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 8 条
  • [1] A supervised analysis of gene-expression profiles of purified clonal plasma cells from patients with systemic light-chain amyloidosis (AL) who have high or low levels of serum free lambda light chains
    Comenzo, R. L.
    Zhou, P.
    Fleisher, M.
    Olshen, A. B.
    XIth International Symposium on Amyloidosis, 2008, : 237 - 239
  • [2] Analysis of Free Serum Light Chains in Patients Suffering from Multiple Myeloma Complicated by Light-Chain Amyloidosis
    Usnarska-Zubkiewicz, Lidia
    Holojda, Jadwiga
    Debski, Jakub
    Zubkiewicz-Zarebska, Anna
    Zagocka, Ewa
    Kuliczkowski, Kazimierz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2014, 23 (04): : 531 - 538
  • [3] Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan
    Zhou, Ping
    Teruya-Feldstein, Julie
    Lu, Ping
    Fleisher, Martin
    Olshen, Adam
    Comenzo, Raymond L.
    BLOOD, 2008, 111 (02) : 549 - 557
  • [4] Gene expression profiling of clonal plasma cells in light chain (AL) amyloidosis by microarray analysis.
    Manske, MK
    Gonzalez-Paz, NC
    Ballman, KV
    Dispenzieri, A
    Price-Troska, TL
    Fonseca, R
    Abraham, RS
    BLOOD, 2003, 102 (11) : 369A - 369A
  • [5] CAN A PERSISTENTLY POSITIVE SERUM OR URINARY IMMUNOFIXATION (SIFE/UIFE), WITH NORMALIZATION OF SERUM FREE LIGHT CHAINS (FLC) ASSAY AND KAPPA/LAMBDA RATIO AFTER TREATMENT, HAVE A PROGNOSTIC IMPACT IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS (AL)?
    De Novellis, D.
    Balsamo, F.
    Pugliese, N.
    Giordano, C.
    Sierchio, L.
    Vasco, A.
    Savoia, M.
    Cerciello, G.
    Pane, F.
    HAEMATOLOGICA, 2020, 105 : S106 - S106
  • [6] The inhibitory Fcγ-receptor IIB (CD32B) is highly expressed on clonal plasma cells from patients with systemic light-chain (AL) amyloidosis and provides a target for monoclonal antibody therapy
    Zhou, P.
    Olshen, A. B.
    Bonvini, E.
    Koenig, S.
    Fleisher, M.
    Young, J.
    Boruchov, A.
    Comenzo, R. L.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2006, 13 : 13 - 14
  • [7] CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy
    Zhou, Ping
    Comenzo, Raymond L.
    Olshen, Adam B.
    Bonvini, Ezio
    Koenig, Scott
    Maslak, Peter G.
    Fleisher, Martin
    Hoffman, James
    Jhanwar, Suresh
    Young, James W.
    Nimer, Stephen D.
    Boruchov, Adam M.
    BLOOD, 2008, 111 (07) : 3403 - 3406
  • [8] The inhibitory Fcy-receptor IIB (CD32B) is highly expressed on clonal plasma cells from patients with systemic light-chain (AL) amyloidosis and provides a target for monoclonal antibody therapy
    Zhou, P.
    Olshen, A. B.
    Bonvini, E.
    Koenig, S.
    Fleisher, M.
    Young, J.
    Boruchov, A.
    Comenzo, R. L.
    XIth International Symposium on Amyloidosis, 2008, : 371 - 373
1